FENC

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Fennec Pharmaceuticals Inc

NASDAQ | FENC

8.25

USD

+$0.00

(

+0.00%

)

At Close (As of Nov 5, 2025)

$225.23M

Market Cap

-

P/E Ratio

-0.45

EPS

$9.92

52 Week High

$3.96

52 Week Low

HEALTHCARE

Sector

FENC Chart

Recent Chart
Price Action

FENC Technicals

Tags:

FENC Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $44M
Total Revenue $48M
Cost Of Revenue $3.2M
Costof Goods And Services Sold $3.2M
Operating Income $2.6M
Selling General And Administrative $23M
Research And Development $307K
Operating Expenses $42M
Investment Income Net -
Net Interest Income -$2.5M
Interest Income $1.7M
Interest Expense $4.1M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1M
Income Before Tax -$71K
Income Tax Expense $365K
Interest And Debt Expense -
Net Income From Continuing Operations -$436K
Comprehensive Income Net Of Tax -
Ebit $2.6M
Ebitda $3.6M
Net Income -$436K

Revenue & Profitability

Earnings Performance

FENC Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $45M
Total Current Assets $44M
Cash And Cash Equivalents At Carrying Value $27M
Cash And Short Term Investments $27M
Inventory $1.1M
Current Net Receivables $13M
Total Non Current Assets $822K
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $3.5M
Other Non Current Assets -
Total Liabilities $51M
Total Current Liabilities $6.9M
Current Accounts Payable $2.9M
Deferred Revenue -
Current Debt -
Short Term Debt $366K
Total Non Current Liabilities $44M
Capital Lease Obligations $2K
Long Term Debt $19M
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $19M
Other Current Liabilities $3.4M
Other Non Current Liabilities -
Total Shareholder Equity -$5.5M
Treasury Stock -
Retained Earnings -$220M
Common Stock $146M
Common Stock Shares Outstanding $27M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow $27M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $800K
Capital Expenditures $0
Change In Receivables -
Change In Inventory $517K
Profit Loss -
Cashflow From Investment -
Cashflow From Financing -$14M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$70K

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $44M
Total Revenue $48M
Cost Of Revenue $3.2M
Costof Goods And Services Sold $3.2M
Operating Income $2.6M
Selling General And Administrative $23M
Research And Development $307K
Operating Expenses $42M
Investment Income Net -
Net Interest Income -$2.5M
Interest Income $1.7M
Interest Expense $4.1M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1M
Income Before Tax -$71K
Income Tax Expense $365K
Interest And Debt Expense -
Net Income From Continuing Operations -$436K
Comprehensive Income Net Of Tax -
Ebit $2.6M
Ebitda $3.6M
Net Income -$436K

FENC News

FENC Profile

Fennec Pharmaceuticals Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Fennec Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Research Triangle Park, North Carolina, dedicated to developing pioneering treatments for cancer, especially among pediatric patients. The company's lead product candidate, Pedmark, targets chemotherapy-induced ototoxicity in children, representing a vital innovation in oncology care. With a strong focus on enhancing patient quality of life, Fennec is well-positioned to make significant advancements in the oncology landscape, both domestically and internationally, as it strives to address unmet medical needs in the pediatric demographic.

CHR
-45.58%
$0.07
NVVE
-8.57%
$0.19
MTC
+626.97%
$2.21
ASST
+18.80%
$1.48
RIVN
+23.36%
$15.42
LNAI
+40.28%
$1.17
NVDA
-1.75%
$195.21
BYND
-4.31%
$1.33
VHAI
0.00%
$0.00
PFE
+1.37%
$24.63
RUBI
-49.75%
$0.30
SNAP
-2.00%
$7.32
PLUG
+4.76%
$2.64
TSLA
+4.00%
$462.07
GRAB
-2.50%
$5.64
YDKG
-5.55%
$0.05
F
+2.69%
$13.13
SMX
+43.53%
$2.11
PLTR
-1.48%
$187.90
INTC
+3.64%
$38.38
DNN
-2.18%
$2.68
WTO
-0.20%
$0.04
AXDX
-61.36%
$0.03
AMD
+2.51%
$256.33
ACHR
+0.26%
$9.58
GPUS
-7.02%
$0.34
T
+0.42%
$24.54
AAL
+6.08%
$13.42
BITF
+5.72%
$4.05
CMBM
+58.82%
$3.24
KVUE
+1.62%
$16.23
ONDS
+0.67%
$6.00
CIFR
+9.77%
$24.71
RXRX
-0.80%
$4.96
SOFI
+2.38%
$30.07
TEVA
+20.16%
$24.58
SMCI
-11.11%
$42.13
BAC
-2.04%
$52.44
ETHD
-15.01%
$4.47
ADAP
-15.14%
$0.05
NFE
+13.99%
$1.53
AMCR
+3.04%
$8.11
BTG
+1.12%
$4.04
WBD
+0.70%
$22.76
IREN
+14.67%
$76.41
AAPL
+0.03%
$270.14
MARA
+3.06%
$17.13
QS
+10.49%
$17.05
VALE
+3.09%
$12.31
DVLT
-7.83%
$1.64
CAN
+16.21%
$1.29
RIG
-0.12%
$3.89
RGTI
+5.99%
$37.29
U
+18.12%
$42.37
WULF
+2.33%
$15.36
RMBL
+60.50%
$3.21
FUBO
+11.00%
$4.08
AMZN
+0.35%
$250.20
ADD
-25.47%
$0.05
NVO
+0.43%
$48.46
BURU
-2.17%
$0.28
EPWK
-6.41%
$0.07
BTBT
+3.14%
$3.28
SRM
+53.27%
$10.30
TLRY
+3.62%
$1.28
BMNR
+4.89%
$41.39
NCLH
-0.95%
$18.61
JOBY
+0.98%
$14.90
ZDAI
+13.94%
$0.52
RIOT
-1.58%
$18.97
HIMS
+3.11%
$44.12
NOK
+0.51%
$6.84
APPS
+23.14%
$7.29
CMG
+0.72%
$31.97
HTZ
-0.81%
$6.67
ALIT
-7.22%
$2.50
HOOD
+4.15%
$142.47
QBTS
+4.37%
$31.04
NGD
+2.48%
$6.80
KDLY
-11.88%
$0.78
GOOGL
-2.17%
$277.54
NIO
+2.30%
$7.32
BBD
+3.47%
$3.52
BW
+28.34%
$4.80
NVTS
-5.73%
$9.86
WLGS
-5.57%
$0.04
MU
+8.93%
$237.50
HPE
+0.59%
$23.70
AG
-7.82%
$10.65
RDHL
+2.77%
$1.11
PLTZ
+2.80%
$6.24
GGB
+5.11%
$3.59
CPNG
-5.94%
$30.22
HBAN
+0.13%
$15.29
ETWO
0.00%
$3.30
PBR
+2.57%
$12.13
ABEV
+1.46%
$2.42
ITUB
+1.55%
$7.49
PCG
+1.57%
$16.16
MSPR
-27.89%
$0.47
CHR
-45.58%
$0.07
NVVE
-8.57%
$0.19
MTC
+626.97%
$2.21
ASST
+18.80%
$1.48
RIVN
+23.36%
$15.42
LNAI
+40.28%
$1.17
NVDA
-1.75%
$195.21
BYND
-4.31%
$1.33
VHAI
0.00%
$0.00
PFE
+1.37%
$24.63
RUBI
-49.75%
$0.30
SNAP
-2.00%
$7.32
PLUG
+4.76%
$2.64
TSLA
+4.00%
$462.07
GRAB
-2.50%
$5.64
YDKG
-5.55%
$0.05
F
+2.69%
$13.13
SMX
+43.53%
$2.11
PLTR
-1.48%
$187.90
INTC
+3.64%
$38.38
DNN
-2.18%
$2.68
WTO
-0.20%
$0.04
AXDX
-61.36%
$0.03
AMD
+2.51%
$256.33
ACHR
+0.26%
$9.58
GPUS
-7.02%
$0.34
T
+0.42%
$24.54
AAL
+6.08%
$13.42
BITF
+5.72%
$4.05
CMBM
+58.82%
$3.24
KVUE
+1.62%
$16.23
ONDS
+0.67%
$6.00
CIFR
+9.77%
$24.71
RXRX
-0.80%
$4.96
SOFI
+2.38%
$30.07
TEVA
+20.16%
$24.58
SMCI
-11.11%
$42.13
BAC
-2.04%
$52.44
ETHD
-15.01%
$4.47
ADAP
-15.14%
$0.05
NFE
+13.99%
$1.53
AMCR
+3.04%
$8.11
BTG
+1.12%
$4.04
WBD
+0.70%
$22.76
IREN
+14.67%
$76.41
AAPL
+0.03%
$270.14
MARA
+3.06%
$17.13
QS
+10.49%
$17.05
VALE
+3.09%
$12.31
DVLT
-7.83%
$1.64
CAN
+16.21%
$1.29
RIG
-0.12%
$3.89
RGTI
+5.99%
$37.29
U
+18.12%
$42.37
WULF
+2.33%
$15.36
RMBL
+60.50%
$3.21
FUBO
+11.00%
$4.08
AMZN
+0.35%
$250.20
ADD
-25.47%
$0.05
NVO
+0.43%
$48.46
BURU
-2.17%
$0.28
EPWK
-6.41%
$0.07
BTBT
+3.14%
$3.28
SRM
+53.27%
$10.30
TLRY
+3.62%
$1.28
BMNR
+4.89%
$41.39
NCLH
-0.95%
$18.61
JOBY
+0.98%
$14.90
ZDAI
+13.94%
$0.52
RIOT
-1.58%
$18.97
HIMS
+3.11%
$44.12
NOK
+0.51%
$6.84
APPS
+23.14%
$7.29
CMG
+0.72%
$31.97
HTZ
-0.81%
$6.67
ALIT
-7.22%
$2.50
HOOD
+4.15%
$142.47
QBTS
+4.37%
$31.04
NGD
+2.48%
$6.80
KDLY
-11.88%
$0.78
GOOGL
-2.17%
$277.54
NIO
+2.30%
$7.32
BBD
+3.47%
$3.52
BW
+28.34%
$4.80
NVTS
-5.73%
$9.86
WLGS
-5.57%
$0.04
MU
+8.93%
$237.50
HPE
+0.59%
$23.70
AG
-7.82%
$10.65
RDHL
+2.77%
$1.11
PLTZ
+2.80%
$6.24
GGB
+5.11%
$3.59
CPNG
-5.94%
$30.22
HBAN
+0.13%
$15.29
ETWO
0.00%
$3.30
PBR
+2.57%
$12.13
ABEV
+1.46%
$2.42
ITUB
+1.55%
$7.49
PCG
+1.57%
$16.16
MSPR
-27.89%
$0.47
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.